Eli Lilly And Company ((LLY)), Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity aims to assess whether combining tirzepatide with mibavademab results in greater weight loss compared to tirzepatide alone. This study is significant as it explores potential advancements in obesity treatment.
The interventions being tested are tirzepatide and mibavademab, both administered subcutaneously. Tirzepatide is a drug designed to aid in weight loss, while mibavademab is being evaluated for its potential to enhance these effects.
The study employs an interventional design with randomized allocation and a parallel intervention model. It is double-blind, meaning both participants and investigators are unaware of the group assignments, ensuring unbiased results. The primary aim is treatment-focused.
Key dates for the study include its start on April 24, 2024, with the last update submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates.
The market implications of this study are significant for Eli Lilly and Regeneron Pharmaceuticals, as positive results could enhance their stock performance and investor confidence. With obesity being a major health concern, successful outcomes could position these companies favorably against competitors in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.